Centene Competitors

Centene (NYSE:CNC) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Centene and Sanofi's net margins, return on equity and return on assets.

Volatility and Risk

Centene has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Institutional & Insider Ownership

91.5% of Centene shares are held by institutional investors. Comparatively, 6.9% of Sanofi shares are held by institutional investors. 1.9% of Centene shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Centene and Sanofi's revenue, earnings per share and valuation.

Sanofi has lower revenue, but higher earnings than Centene. Centene is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Centene and Sanofi, as provided by MarketBeat.

Centene presently has a consensus price target of $83.8333, indicating a potential upside of 37.59%. Sanofi has a consensus price target of $57.00, indicating a potential upside of 14.85%. Given Centene's stronger consensus rating and higher possible upside, analysts plainly believe Centene is more favorable than Sanofi.

Summary

Centene beats Sanofi on 8 of the 14 factors compared between the two stocks.

Centene (NYSE:CNC) and GlaxoSmithKline (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Centene and GlaxoSmithKline's net margins, return on equity and return on assets.

Volatility and Risk

Centene has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

Institutional & Insider Ownership

91.5% of Centene shares are held by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are held by institutional investors. 1.9% of Centene shares are held by insiders. Comparatively, 10.0% of GlaxoSmithKline shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Centene and GlaxoSmithKline's revenue, earnings per share and valuation.

GlaxoSmithKline has lower revenue, but higher earnings than Centene. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Centene, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Centene and GlaxoSmithKline, as provided by MarketBeat.

Centene presently has a consensus price target of $83.8333, indicating a potential upside of 37.59%. Given Centene's stronger consensus rating and higher possible upside, analysts plainly believe Centene is more favorable than GlaxoSmithKline.

Summary

Centene beats GlaxoSmithKline on 8 of the 15 factors compared between the two stocks.

Centene (NYSE:CNC) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Earnings and Valuation

This table compares Centene and Stryker's revenue, earnings per share and valuation.

Stryker has lower revenue, but higher earnings than Centene. Centene is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

91.5% of Centene shares are held by institutional investors. Comparatively, 71.5% of Stryker shares are held by institutional investors. 1.9% of Centene shares are held by insiders. Comparatively, 6.8% of Stryker shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Centene and Stryker, as provided by MarketBeat.

Centene presently has a consensus price target of $83.8333, indicating a potential upside of 37.59%. Stryker has a consensus price target of $227.4783, indicating a potential downside of 5.04%. Given Centene's stronger consensus rating and higher possible upside, analysts plainly believe Centene is more favorable than Stryker.

Volatility and Risk

Centene has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Profitability

This table compares Centene and Stryker's net margins, return on equity and return on assets.

Summary

Stryker beats Centene on 10 of the 14 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Centene (NYSE:CNC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Earnings & Valuation

This table compares Intuitive Surgical and Centene's revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has higher earnings, but lower revenue than Centene. Centene is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

86.5% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 91.5% of Centene shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 1.9% of Centene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Intuitive Surgical and Centene, as reported by MarketBeat.com.

Intuitive Surgical currently has a consensus price target of $736.0588, indicating a potential downside of 2.12%. Centene has a consensus price target of $83.8333, indicating a potential upside of 37.59%. Given Centene's stronger consensus rating and higher possible upside, analysts plainly believe Centene is more favorable than Intuitive Surgical.

Volatility and Risk

Intuitive Surgical has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Centene has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.

Profitability

This table compares Intuitive Surgical and Centene's net margins, return on equity and return on assets.

Summary

Centene beats Intuitive Surgical on 8 of the 15 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Centene (NYSE:CNC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Gilead Sciences and Centene, as reported by MarketBeat.com.

Gilead Sciences currently has a consensus price target of $94.3793, indicating a potential upside of 38.47%. Centene has a consensus price target of $83.8333, indicating a potential upside of 37.59%. Given Gilead Sciences' higher possible upside, equities research analysts plainly believe Gilead Sciences is more favorable than Centene.

Profitability

This table compares Gilead Sciences and Centene's net margins, return on equity and return on assets.

Institutional and Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 91.5% of Centene shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 1.9% of Centene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Gilead Sciences and Centene's revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher earnings, but lower revenue than Centene. Gilead Sciences is trading at a lower price-to-earnings ratio than Centene, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Centene has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.

Summary

Gilead Sciences beats Centene on 9 of the 15 factors compared between the two stocks.

Centene (NYSE:CNC) and Anthem (NYSE:ANTM) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Centene and Anthem, as reported by MarketBeat.

Centene currently has a consensus target price of $83.8333, indicating a potential upside of 37.59%. Anthem has a consensus target price of $353.3684, indicating a potential upside of 12.05%. Given Centene's stronger consensus rating and higher probable upside, analysts clearly believe Centene is more favorable than Anthem.

Profitability

This table compares Centene and Anthem's net margins, return on equity and return on assets.

Institutional and Insider Ownership

91.5% of Centene shares are owned by institutional investors. Comparatively, 89.4% of Anthem shares are owned by institutional investors. 1.9% of Centene shares are owned by company insiders. Comparatively, 0.2% of Anthem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Centene and Anthem's top-line revenue, earnings per share and valuation.

Anthem has higher revenue and earnings than Centene. Centene is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Centene has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Anthem has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Summary

Anthem beats Centene on 9 of the 15 factors compared between the two stocks.